Table 2.
Age (Years) | Men |
Women |
Overall prevalence [95% exact CI] | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
18–19 (n = 49) | 20–24 (n = 254) | 25–29 (n = 76) | 30–34 (n = 33) | Total (n = 422) | 18–19 (n = 56) | 20–24 (n = 266) | 25–29 (n = 73) | 30–34 (n = 29) | Total (n = 424) | ||
Chlamydia | 4.1% | 3.4% | 0.0% | 3.0% | 2.8% | 1.8% | 3.4% | 2.7% | 0.0% | 2.8% | 2.8% [1.8%–4.2%] |
Gonorrhoea | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 5.4% | 4.1% | 5.5% | 6.9% | 4.7% | 2.4% [1.4%–3.6%] |
Syphilis | 0.0% | 0.4% | 1.3% | 3.0% | 0.7% | 3.6% | 1.9% | 2.7% | 6.9% | 2.6% | 1.6% [0.8%–2.8%] |
HSV-2a | 6.1% | 10.6% | 14.5% | 42.4% | 13.3% | 25.0% | 42.9% | 56.2% | 72.4% | 44.8% | 29.1% [26.0%–32.3%] |
HSV-2b | 6.3% | 11.2% | 17.7% | 48.3% | 14.4% | 27.5% | 46.5% | 60.3% | 77.8% | 48.4% | 31.5% [28.2%–34.9%] |
HIV | 7.8% | 21.2% | 14.8% [12.2%–17.1%] | ||||||||
HIV/STI coinfectionc | 3.1% | 16.9% | 10.0% [8.1%–12.3%] |
Indeterminates counted as negatives.
Indeterminates dropped from analysis.
Infection with HIV in addition to any other STI.